No Data
RBC Capital Maintains Outperform on PTC Therapeutics, Raises Price Target to $63
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $63
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ) and PTC Therapeutics (PTCT)
Citi Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Raises Target Price to $45
PTC Therapeutics Price Target Raised to $45 From $32 at Citi
